You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

The Role of Aromatase Inhibitors in Adjuvant Therapy for Postmenopausal Women with Hormone Receptor-positive Breast Cancer

ID: 1-18 May 2012
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
Breast Cancer Disease Site Group

Patient Population

Postmenopausal women with early-stage, hormone receptor-positive breast cancer

Research Question(s)

In postmenopausal women with early-stage, hormone receptor-positive breast cancer:

  1. Compared with adjuvant tamoxifen alone for five years, do adjuvant aromatase inhibitors (anastrozole, letrozole, or exemestane) alone for five years improve clinically meaningful outcomes (disease-free or overall survival)?
  2. Compared with adjuvant tamoxifen alone for five years, do adjuvant aromatase inhibitors in sequence with tamoxifen for a total of five years improve clinically meaningful outcomes?
  3. Compared with placebo, do aromatase inhibitors after five years of adjuvant tamoxifen therapy improve clinically meaningful outcomes?
  4. Compared with tamoxifen or placebo, what are the harms associated with aromatase inhibitors?
  5. Compared with tamoxifen, does the efficacy of aromatase inhibitors depend on p185HER2/neu glycoprotein expression?